Autism spectrum disorder (ASD) is a complex neurodevelopmental condition with heterogeneous presentations. Growing evidence implicates neuroinflammation, immune dysregulation, and mitochondrial dysfunction in ASD pathophysiology — biological targets where MSC therapy has demonstrated measurable effects.
The Neuroinflammation Hypothesis
Post-mortem brain studies and neuroimaging in ASD consistently show activated microglia and elevated pro-inflammatory cytokines — particularly in the cerebellum and prefrontal cortex. MSC therapy's immunomodulatory mechanism targets this neuroinflammatory environment, which is the biological rationale for investigating it in ASD.
Published Research
A 2020 randomized controlled trial published in Stem Cells Translational Medicine evaluated intrathecal + IV MSC therapy in children with ASD aged 4–12. At 24 weeks, the MSC group showed statistically significant improvements on the Childhood Autism Rating Scale (CARS) and Social Responsiveness Scale (SRS), with particularly strong improvements in social communication and behavioral flexibility. Adverse events were mild and transient.
Several observational studies from Russia, Iran, and China report similar findings — improved eye contact, language initiation, and reduced repetitive behaviors at 3–6 months post-treatment.
Important Context
We approach ASD with honesty: the evidence base is still developing, and outcomes are highly variable. Not every child responds, and the degree of improvement varies significantly. We do not accept patients with ASD solely based on a parent's hope — we evaluate whether the clinical profile is consistent with an inflammatory/immune subtype of ASD where evidence is strongest. This assessment happens on the evaluation call.